Current status of thrombolysis for peripheral arterial occlusive disease

Annals of Vascular Surgery

Volumn 16, Issue 6, 2002, Pages 797-804

  Ouriel, Kenneth ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; ANTIPYRETIC AGENT; ENZYME ANTIBODY; FIBRINOLYTIC AGENT; PLASMINOGEN ACTIVATOR; PROLYSE; PROUROKINASE; RECOMBINANT ENZYME; RECOMBINANT UROKINASE; RETEPLASE; STREPTODORNASE PLUS STREPTOKINASE; STREPTOKINASE; STREPTOKINASE DERIVATIVE; TENECTEPLASE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; UROKINASE;

BLEEDING; BLOOD CLOT; BLOOD CLOT LYSIS; BYPASS SURGERY; CLINICAL TRIAL; DRUG USE; EMBOLISM; FEVER; FIBRINOLYTIC THERAPY; GRAFT OCCLUSION; HUMAN; HYPOTENSION; LEG BLOOD FLOW; LIMB ISCHEMIA; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREVALENCE; PRIORITY JOURNAL; REVASCULARIZATION; REVIEW; RHEUMATIC HEART DISEASE; STANDARD; THROMBECTOMY; THROMBOSIS; VASCULAR SURGERY; MORTALITY; PERIPHERAL VASCULAR DISEASE;

ARTERIAL OCCLUSIVE DISEASES; CLINICAL TRIALS; HOSPITAL MORTALITY; HUMANS; PERIPHERAL VASCULAR DISEASES; PLASMINOGEN ACTIVATORS; THROMBOLYTIC THERAPY;

EID: 0036878317     PISSN: 08905096     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10016-001-0318-y     Document Type: Article

References (35)

1. Blaisdell FW, Steele M, Allen RE. Management of acute lower extremity arterial ischemia due to embolism and thrombosis. Surgery 1978;84:822-834.
2. Jivegård L, Holm J, Scherstén T. Acute limb ischemia due to arterial embolism or thrombosis: influence of limb ischemia versus pre-existing cardiac disease on postoperative mortality rate. J Cardiovasc Surg 1988;29:32-36.
3. Holm J, Scherstén T. Anticoagulant treatment during and after embolectomy. Acta Chir Scand 1972;138(683):687.
4. Caruana JA, Gutierrez IZ, Andersen MN, et al. Factors that affect the outcome of peripheral arterial embolization. Arch Surg 1981;116:423-425.
5. Ouriel K, Shortell CK, DeWeese JA, et al. A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral arterial ischemia. J Vasc Surg 1994;19:1021-1030.
6. Ouriel K, Veith FJ, Sasahara AA. A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. N Engl J Med 1998;338:1105-1111.
7. Anonymous. Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity. The STILE trial. Ann Surg discussion 1994;220:251-266.
8. Ouriel K, Kandarpa K, Schuerr DM, Hultquist M, Hodkinson B, Wallin B. Prourokinase versus urokinase for recanalization of peripheral occlusions, safety and efficacy: the PURPOSE trial. J Vasc Interv Radiol 1999;10:1083-1091.
9. Dormandy J, Heeck L, Vig S. Acute limb ischemia. Semin vasc Surg 1999;12:148-153.
10. McNamara TO, Fischer JR. Thrombolysis of peripheral arterial and graft occlusions: improved results using high-dose urokinase. AJR Am J Roentgenol 1985;144:769-775.
11. Semba CP, Murphy TP, Bakal CW, Calis KA, Matalon TA. Thrombolytic therapy with use of alteplase (rt-PA) in peripheral arterial occlusive disease: review of the clinical literature. The Advisory Panel. J Vasc Interv Radiol 2 Pt 1 2000;11:149-161.
12. Ouriel K, Katzen B, Mewissen MW, et al. Reteplase in the treatment of peripheral arterial and venous occlusion. J Vasc Interv Radiol 2000;11:849-854.
13. McNamara TO. Thrombolysis as the initial treatment for acute lower limb ischemia. In: Comerota AJ ed. J.B. Lippincott, Philadelphia, 1997pp 253-268.
14. Faggioli GL, Peer RM, Pedrini L, et al. Failure of thrombolytic therapy to improve long-term vascular patency. J Vasc Surg 1994;19:289-296.
15. Korn P, Khilnani NM, Fellers JC, et al. Thrombolysis for native arterial occlusions of the lower extremities: clinical outcome and cost. J Vasc Surg 2001;33:1148-1157.
16. Sullivan KL, Gardiner GAJ, Kandarpa K, et al. Efficacy of thrombolysis in infrainguinal bypass grafts. Circulation 1991;83 (2 Suppl):99-105.
17. Milstone H. A factor in normal human blood which participates in streptococcal fibrinolysis. J Immunol 42:116.
18. Onundarson PT, Haraldsson HM, Bergmann L, Francis CW, Marder VJ. Plasminogen depletion during streptokinase treatment or two-chain urokinase incubation correlates with decreased clot lysability ex vivo and in vitro. Thromb Haemost 1993;70:998-1004.
19. Tillett WS, Garner RL. The fibrinolytic activity of hemolytic streptococci. J Exp Med 1933;58:485.
20. Tillett WS, Sherry S. The effect in patients of streptococcal fibrinolysin (streptokinase) and streptococcal desoxyribonuclease on fibrinous, purulent, and sanguinous pleural exudations. J Clin Invest 1949;28:173.
21. Tillett WS, Johnson AJ, McCarty WR. The intravenous infusion of the streptococcal fibrinolytic principle (streptokinase) into patients. J Clin Invest 1955;34:169-185.
22. Cliffton EE. The use of plasmin in humans. Ann NY Acad Sci 1957;68:209-229.
23. Jostring H, Barth U, Naidu R. Changes of antistreptokinase titer following long-term streptokinase therapy. In: Martin M, Schoop W, Hirsh J eds. Hans Huber, Vienna, 1978pp 110.
24. Macfarlane RG, Pinot JJ. Fibrinolytic activity of normal urine. Nature 1947;159:779.
25. Sobel GW, Mohler SR, Jones NW, Dowdy ABC, Guest MM. Urokinase: an activator of plasma fibrinolysin extracted from urine. Am J Physiol 1952;171:768-769.
26. Credo RB, Burke SE, Barker WM, et al. Recombinant uro-kinase (r-UK): biochemistry, pharmacology, and clinical experience. In: Sasahara AA, Loscalzo J eds. Marcel Dekker, New York, 1978 pp 513-537.
27. Husain SS, Lipinski B, Gurewich V, et al. (1979) Isolation of plasminogen activators useful as therapeutic and diagnostic agents (single-chain, high-fibrin affinity urokinase). U.S. Patent # 4,381, 346.
28. Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator: role of fibrin. J Biol Chem 1982;257:2912.
29. The Gusto Investigators.. An International randomized trial comparing four thrombolytic therapies for acute myocardial infarction. N Engl J Med 1993;329:673-682.
30. Cannon CP, Gibson CM, McCabe CH, et al. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. Circulation 1998;98:2805-2814.
31. Meierhenrich R, Carlsson J, Seifried E, et al. Effect of reteplase on hemostasis variables: analysis of fibrin specificity, relation to bleeding complications and coronary patency. Int J Cardiol 1998;65:57-63.
32. Valji K. Evolving strategies for thrombolytic therapy of peripheral vascular occlusion. J Vasc Inter Radiol 2000;11:411-420.
33. Weaver FA, Comerota AJ, Youngblood M, Froehlich J, Hosking JD, Papanicolaou G. Surgical revascularization versus thrombolysis for nonembolic lower extremity native artery occlusions: results of a prospective randomized trial. The STILE Investigators. Surgery versus thrombolysis for ischemia of the lower extremity. J Vasc Surg 1996;24:513-521.
34. Comerota AJ, Weaver FA, Hosking JD, et al. Results of a prospective, randomized trial of surgery versus thrombolysis for occluded lower extremity bypass grafts. Am J Surg 1996;172:105-112.
35. Ouriel K, Veith FJ, Sasahara AA. Thrombolysis or peripheral arterial surgery: phase I results. TOPAS Investigators. J Vasc Surg 1996;23:64-73.